Ocugen Inc (OCGN)

$1.47 -0.01 (-0.68%)
Market Cap 501.01M
Revenue (ttm) 4.41M
Net Income (ttm) -67.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,538.55%
Debt to Equity Ratio -2.37
Volume 6,724,000
Avg Vol 9,657,656
Day's Range N/A - N/A
Shares Out 338.52M
Stochastic %K 17%
Beta 2.30
Analysts Strong Sell
Price Target $11.57

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484-328-4701
Address:
11 Great Valley Parkway, Malvern, United States
VINCENZOCOCCOTTI
VINCENZOCOCCOTTI May. 13 at 11:51 AM
$OCGN
0 · Reply
RamboKB
RamboKB May. 13 at 11:40 AM
$OCGN
0 · Reply
hastorian
hastorian May. 13 at 11:17 AM
$OCGN https://ir.ocugen.com/news-releases/news-release-details/ocugen-participate-upcoming-may-scientific-and-investor
0 · Reply
Hrumph63
Hrumph63 May. 13 at 11:11 AM
$OCGN time for the morning wipe…
0 · Reply
Pit1908
Pit1908 May. 13 at 11:09 AM
$OCGN ⏳🧬🫱🏻‍🫲🏼🌍🌏🌎
0 · Reply
Perso
Perso May. 13 at 11:08 AM
$OCGN https://www.stocktitan.net/news/OCGN/ocugen-to-participate-in-upcoming-may-scientific-and-investor-q336wgb0z5u3.html
0 · Reply
BrunoMonteiro
BrunoMonteiro May. 13 at 9:59 AM
$OCGN feels like macro is slowly shifting. USA and China could be huge for risk assets. 🤞
0 · Reply
SmoldyShatStone
SmoldyShatStone May. 13 at 7:26 AM
$OCGN for a second I was so happy to see Shanky was taken off the company leadership page…I thought you baggies would finally have some hope but refreshed and realized you guys are still gonna get Shanked 😂
0 · Reply
Tomassso
Tomassso May. 13 at 7:14 AM
$OCGN Shankar is already prepared to receive trillion dollars of free funding: https://www.thenationalnews.com/news/uae/2026/05/10/sheikh-mohammed-bin-rashid-announces-scheme-to-eradicate-river-blindness/
0 · Reply
Tomassso
Tomassso May. 13 at 6:19 AM
$OCGN glad that Huma left. Shankar is next. She was oy interested in hand bags and latest designer shoes
1 · Reply
Latest News on OCGN
Ocugen to Participate in Upcoming May Scientific and Investor Conferences

May 13, 2026, 7:02 AM EDT - 57 minutes ago

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

Ocugen reports Q1 EPS (6c), consensus (5c)

2026-05-05T13:15:52.000Z - 7 days ago

Ocugen reports Q1 EPS (6c), consensus (5c)

Ocugen Provides Business Update with First Quarter 2026 Financial Results

May 5, 2026, 8:32 AM EDT - 7 days ago

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 7 days ago

Ocugen Earnings Call Transcript: Q1 2026

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

May 5, 2026, 8:12 AM EDT - 7 days ago

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen announces private offering of $115M of convertible senior notes

2026-05-04T20:16:05.000Z - 8 days ago

Ocugen announces private offering of $115M of convertible senior notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

May 4, 2026, 4:01 PM EDT - 8 days ago

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Apr 29, 2026, 7:02 AM EDT - 14 days ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Ocugen to Present at April 2026 Investor and Industry Conferences

Apr 23, 2026, 7:02 AM EDT - 20 days ago

Ocugen to Present at April 2026 Investor and Industry Conferences

Ocugen completes dosing in GARDian3 trial

2026-04-01T11:56:15.000Z - 6 weeks ago

Ocugen completes dosing in GARDian3 trial

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Apr 1, 2026, 7:02 AM EDT - 6 weeks ago

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen price target raised to $12 from $8 at Noble Capital

2026-03-25T13:20:15.000Z - 6 weeks ago

Ocugen price target raised to $12 from $8 at Noble Capital

Ocugen price target raised to $10 from $7 at H.C. Wainwright

2026-03-25T10:11:21.000Z - 7 weeks ago

Ocugen price target raised to $10 from $7 at H.C. Wainwright

Ocugen Transcript: Study update

Mar 24, 2026, 8:00 AM EDT - 7 weeks ago

Ocugen Transcript: Study update

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

2026-03-24T11:55:27.000Z - 7 weeks ago

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Mar 24, 2026, 7:45 AM EDT - 7 weeks ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Mar 23, 2026, 7:02 AM EDT - 7 weeks ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Ocugen initiated with a Buy at Canaccord

2026-03-17T11:30:27.000Z - 2 months ago

Ocugen initiated with a Buy at Canaccord

Ocugen initiated with an Outperform at Oppenheimer

2026-03-11T10:40:53.000Z - 2 months ago

Ocugen initiated with an Outperform at Oppenheimer

Ocugen price target raised to $22 from $15 at Lucid Capital

2026-03-11T10:10:53.000Z - 2 months ago

Ocugen price target raised to $22 from $15 at Lucid Capital

Ocugen Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 2 months ago

Ocugen Earnings Call Transcript: Q4 2025

Ocugen reports Q4 EPS (6c), consensus (6c)

2026-03-04T13:28:15.000Z - 2 months ago

Ocugen reports Q4 EPS (6c), consensus (6c)

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 8:15 AM EST - 2 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Options Volatility and Implied Earnings Moves Today, March 04, 2026

2026-03-04T12:06:21.000Z - 2 months ago

Options Volatility and Implied Earnings Moves Today, March 04, 2026

CHPT MVIS OKTA RGTI SE STEM VEEV

Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete

2026-03-02T12:34:12.000Z - 2 months ago

Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Mar 2, 2026, 7:02 AM EST - 2 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Ocugen appoints Rita Johnson-Greene as CFO

2026-02-09T12:20:16.000Z - 3 months ago

Ocugen appoints Rita Johnson-Greene as CFO

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Feb 9, 2026, 7:02 AM EST - 3 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 23, 2026, 8:00 AM EST - 3 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Ocugen prices 15M shares at $1.50 in underwritten offering

2026-01-21T13:35:36.000Z - 3 months ago

Ocugen prices 15M shares at $1.50 in underwritten offering

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 3 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Ocugen Transcript: Study result

Jan 15, 2026, 8:30 AM EST - 4 months ago

Ocugen Transcript: Study result

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 15, 2026, 8:15 AM EST - 4 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 13, 2026, 7:00 AM EST - 4 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 12, 2026, 6:30 AM EST - 4 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Jan 9, 2026, 7:02 AM EST - 4 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 10, 2025, 9:20 AM EST - 5 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 20, 2025, 7:02 AM EST - 6 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Ocugen Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 6 months ago

Ocugen Earnings Call Transcript: Q3 2025

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Nov 5, 2025, 6:30 AM EST - 6 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 7 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Sep 25, 2025, 9:30 AM EDT - 8 months ago

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 15, 2025, 6:03 AM EDT - 8 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 9 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 9 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 9 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 9 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen Earnings Call Transcript: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 10 months ago

Ocugen Earnings Call Transcript: Q2 2025

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 10 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 10 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 10 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 10 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 11 months ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 11 months ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 1 year ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q1 2025

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 1 year ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings Call Transcript: Q4 2024

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 1 year ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 8:00 AM EST - 1 year ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 12, 2025, 7:42 AM EST - 1 year ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Feb 3, 2025, 6:30 AM EST - 1 year ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 27, 2025, 6:30 AM EST - 1 year ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Jan 16, 2025, 7:30 AM EST - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Jan 13, 2025, 6:30 AM EST - 1 year ago

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Dec 19, 2024, 6:38 AM EST - 1 year ago

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

VINCENZOCOCCOTTI
VINCENZOCOCCOTTI May. 13 at 11:51 AM
$OCGN
0 · Reply
RamboKB
RamboKB May. 13 at 11:40 AM
$OCGN
0 · Reply
hastorian
hastorian May. 13 at 11:17 AM
$OCGN https://ir.ocugen.com/news-releases/news-release-details/ocugen-participate-upcoming-may-scientific-and-investor
0 · Reply
Hrumph63
Hrumph63 May. 13 at 11:11 AM
$OCGN time for the morning wipe…
0 · Reply
Pit1908
Pit1908 May. 13 at 11:09 AM
$OCGN ⏳🧬🫱🏻‍🫲🏼🌍🌏🌎
0 · Reply
Perso
Perso May. 13 at 11:08 AM
$OCGN https://www.stocktitan.net/news/OCGN/ocugen-to-participate-in-upcoming-may-scientific-and-investor-q336wgb0z5u3.html
0 · Reply
BrunoMonteiro
BrunoMonteiro May. 13 at 9:59 AM
$OCGN feels like macro is slowly shifting. USA and China could be huge for risk assets. 🤞
0 · Reply
SmoldyShatStone
SmoldyShatStone May. 13 at 7:26 AM
$OCGN for a second I was so happy to see Shanky was taken off the company leadership page…I thought you baggies would finally have some hope but refreshed and realized you guys are still gonna get Shanked 😂
0 · Reply
Tomassso
Tomassso May. 13 at 7:14 AM
$OCGN Shankar is already prepared to receive trillion dollars of free funding: https://www.thenationalnews.com/news/uae/2026/05/10/sheikh-mohammed-bin-rashid-announces-scheme-to-eradicate-river-blindness/
0 · Reply
Tomassso
Tomassso May. 13 at 6:19 AM
$OCGN glad that Huma left. Shankar is next. She was oy interested in hand bags and latest designer shoes
1 · Reply
Tomassso
Tomassso May. 13 at 6:17 AM
$OCGN So, Shankar gets millions, this tanks, and he will do a reverse split. He's a genius!!!
0 · Reply
nick2341
nick2341 May. 13 at 5:38 AM
$OCGN good morning 🌅. Hoping for a green 💚 day
0 · Reply
BoogerBanditt
BoogerBanditt May. 13 at 4:46 AM
$OCGN going to barcode until the next major catalyst.
1 · Reply
dgiudice
dgiudice May. 13 at 4:31 AM
$OCGN Carries the stink of The Legendary King. LOL.
0 · Reply
Chicagomuni2pro
Chicagomuni2pro May. 13 at 3:08 AM
$OCGN
0 · Reply
Perso
Perso May. 13 at 2:47 AM
$OCGN https://www.ad-hoc-news.de/boerse/news/ueberblick/ocugen-s-clinical-calendar-packs-a-punch-in-q3-as-analysts-stay-bullish/69318205
0 · Reply
Mr_Stockers
Mr_Stockers May. 13 at 2:11 AM
$OCGN I gotta say, the Short Intrest on OCGN is staggering! I'd ❤️ to see a GameStop type senerio happen here, and see those lil shorties 🔥
2 · Reply
Gdizzle69
Gdizzle69 May. 13 at 1:57 AM
$OCGN Huma is out, our new boy Mohamed is in. Did some quick googling and he has a very strong background. Extremely excited. Hopefully he can use his power in Oculand and help Ocugen succeed. Seems as if he will be a Solid fit, and keep Shankar from blowing it right before the big leagues.
3 · Reply
bultishch
bultishch May. 13 at 1:25 AM
$OCGN our time will come
0 · Reply
Bulldog_Retired
Bulldog_Retired May. 13 at 1:05 AM
$OCGN so the incoming head of the FDA is from the "F" side not the "D" side and is a "Mr." not a "Dr.", so hope he has a good staff https://www.theguardian.com/us-news/2025/feb/25/kyle-diamantas-fda
0 · Reply
MaesTechnicalAnalysis
MaesTechnicalAnalysis May. 13 at 1:05 AM
$OCGN volume has slowly been increasing? Ocufam is happy https://youtu.be/Xorjj9y3nr4?si=kYMc6KIvBPKuofv-
0 · Reply
justAtool
justAtool May. 13 at 12:13 AM
$OCGN
0 · Reply